Effects of Plasma Exchange Combined with Immunoglobulin Therapy on Consciousness, Immune Function, and Prognosis in Patients with Myasthenia Gravis Crisis: A Prospective Randomized Test
Open Access
- 30 June 2022
- journal article
- retracted article
- Published by Hindawi Limited in Computational and Mathematical Methods in Medicine
- Vol. 2022, 1-7
- https://doi.org/10.1155/2022/7796833
Abstract
Background. Myasthenia gravis (MG) is an acquired autoimmune disease. The main clinical features of MG are skeletal muscle fatigue and pathological fatigue, which worsen at night or after fatigue, such as dyspnea, dysphagia, and systemic weakness. Plasma exchange (PE) is often used in patients with acute exacerbation of MG. Intravenous immunoglobulin (IVIG) is a collection of immunoglobulins from thousands of donors. IVIG can replace a variety of immunosuppressants or PE. However, the effect of PE or IVIG on patients’ consciousness, immune function, and prognosis is not clear. Objective. A prospective randomized test of the effects of PE combined with immunoglobulin on consciousness, immune function, and prognosis in patients with myasthenia gravis crisis (MGC). Methods. Sixty patients with MGC treated from February 2019 to April 2021 were enrolled in our hospital. The cases who received PE were set as the PE group, and those who received PE combined with immunoglobulin were set as the PE+immunoglobulin group. The efficacy, clinical score, state of consciousness, immune function, acetylcholine receptor antibody (AChR-Ab), lymphocyte (LYM), albumin (ALB) levels, and the incidence of adverse reactions were compared. Results. The improvement rate was 100.005% in the treatment group and 83.33% in the PE group. After treatment, the clinical score of the PE+immunoglobulin group was lower than that of the PE group, and the clinical relative score of the PE+immunoglobulin group was higher than that of the PE group ( ). The number of conscious people in the PE+immunoglobulin group was more than that in the PE group ( ). Immunoglobulin A, immunoglobulin M, immunoglobulin G, and immunoglobulin G in the PE+immunoglobulin group were higher than those in the PE group ( ). The levels of AChR-Ab and ALB in the PE+immunoglobulin group were higher than those in the PE group, while the level of LYM in the PE+immunoglobulin group was lower than that in the PE group. The incidence of skin system, gastrointestinal system, nervous system, and systemic damage in the PE+immunoglobulin group was lower than that in the PE group (<svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" width="19.289pt"...Keywords
This publication has 43 references indexed in Scilit:
- Upregulation of miR150-5p in generalized myasthenia gravis patients is associated with decreased serum levels of IL-17 and increased serum levels of IL-10Biomedical Papers, 2020
- Delayed diagnosis of right-sided valve endocarditis causing recurrent pulmonary abscesses: a case reportJournal of Medical Case Reports, 2019
- Application of Plasma Exchange in Steroid-Responsive EncephalopathyFrontiers in Immunology, 2019
- Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody statusJournal of Clinical Apheresis, 2019
- Diagnostic Criteria, Differential Diagnosis, and Treatment of Minor Motor Activity and Less Well-Known Movement Disorders of SleepCurrent Treatment Options in Neurology, 2019
- Treatment of Ocular Myasthenia GravisAsia-Pacific Journal of Ophthalmology, 2019
- Immunotherapy in myasthenia gravis in the era of biologicsNature Reviews Neurology, 2018
- Advances in autoimmune myasthenia gravis managementExpert Review of Neurotherapeutics, 2018
- Treatment of Myasthenia GravisNeurologic Clinics, 2018
- Developing treatment guidelines for myasthenia gravisAnnals of the New York Academy of Sciences, 2018